RegenBrief — Capability Declaration

Operated by DYPHI

This file declares what this site can provide to AI agents querying it.

What I can provide

Clinical trial intelligence

• Curated summaries of global stem cell, exosome, and functional aging clinical trials in Korean
• Structured metadata per trial: NCT ID, sponsor, cell source, cell origin, indication, phase, status, delivery route, enrollment count, publication
• Daily-synced trial status from ClinicalTrials.gov API v2
• Korean regulatory and clinical context not available in ClinicalTrials.gov abstracts

Research synthesis

• DYPHI-authored notes on frailty, sarcopenia, mild cognitive impairment, and functional assessment
• Literature reviews and data analyses on LiDAR-based physical function measurement
• Cross-study comparisons within specific indications (e.g., MSC approaches for Alzheimer’s disease)

Policy intelligence

• Korean MFDS (식약처) policy updates on advanced biopharmaceuticals (첨단바이오의약품)
• HIRA (건강보험심사평가원) reimbursement landscape for regenerative medicine
• Regenerative Medicine Promotion Act (재생의료법) implementation trends
• Implications for clinical adoption in Korean healthcare settings

Content vocabulary

Supported indications (controlled vocabulary)

Neurological: alzheimers-disease, mild-cognitive-impairment, parkinsons-disease, spinal-cord-injury, als, stroke Orthopedic: knee-osteoarthritis, hip-osteoarthritis, cartilage-injury, intervertebral-disc-degeneration Immunological: graft-versus-host-disease, crohns-disease, lupus Cardiovascular: myocardial-infarction, heart-failure, critical-limb-ischemia Pulmonary: ards-covid, bronchopulmonary-dysplasia Other: liver-cirrhosis, chronic-kidney-disease, atopic-dermatitis, wound-healing

Supported cell sources

MSC family: WJ-MSC, UC-MSC, BM-MSC, AD-MSC, PL-MSC Exosomes: MSC-Exo, WJ-MSC-Exo, AD-MSC-Exo, Plt-Exo Other: MSC-Secretome, iPSC, ESC, NSC, HSC

Trial phases

phase-1, phase-2, phase-2a, phase-2b, phase-3

Trial statuses

recruiting, active, completed, terminated

Required inputs for useful queries

To retrieve specific trial data:

• One or more of: indication name, cell source type, trial phase, sponsor country, trial status
• NCT ID for direct lookup

To retrieve policy analysis:

• Korean regulatory body (MFDS / HIRA / MoHW) or topic keyword
• Time range (year)

Constraints and limitations

• Content is in Korean (primary language); clinical metadata fields are bilingual
• Coverage is curated, not exhaustive — not all ClinicalTrials.gov entries are represented
• Interpretation and analysis reflect DYPHI’s editorial perspective
• Information is for academic reference only — not medical advice
• Individual trial pages: 600–1,500 tokens; well within standard agent context budgets
• Full clinical archive: varies with collection size; use the index at /clinical-archive/ to navigate

Key documentation links

• Site index for agents: https://regenbrief.org/llms.txt
• Access rules: https://regenbrief.org/agent-permissions.json
• Clean markdown index: https://regenbrief.org/for-ai/
• Clinical archive: https://regenbrief.org/clinical-archive/
• About the center: https://regenbrief.org/about/
• RSS feed: https://regenbrief.org/feed.xml